Loading clinical trials...
Loading clinical trials...
An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors
Conditions
Interventions
ASN004
Locations
4
United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
NEXT Oncology
Austin, Texas, United States
NEXT Oncology
San Antonio, Texas, United States
Next Oncology
Fairfax, Virginia, United States
Start Date
April 8, 2022
Primary Completion Date
May 8, 2024
Completion Date
May 8, 2024
Last Updated
July 10, 2024
NCT06144671
NCT04570423
NCT06132828
NCT07177937
NCT07489378
NCT06926283
Lead Sponsor
Kirilys Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions